Recce Pharmaceuticals has secured patent acceptance in China for its synthetic anti-infectives technology, extending protection until 2041 and expanding access to the world’s second-largest pharmaceutical market. Patent Specifications ComponentCoverageApplicationProductsR327, R529Anti-infective compoundsExpiry2041Long-term protectionMarket SizeUS$4.09BChinese antibiotic marketGrowth Rate5.7% CAGR2025-2030 projectionPatent Family5th acceptanceGlobal portfolio Treatment Applications ConditionDelivery MethodImplementationBacterial InfectionsMultiple routesComprehensive coverageViral InfectionsVarious formatsFlexible applicationSkin InfectionsTopical optionsDirect treatmentRespiratory IssuesInhalation deliveryTargeted therapySystemic TreatmentInjectable formsMultiple pathways ASX Announcement ASX RCE – China Patent Acceptance Strengthens Global Anti-Infective PortfolioDownloadUninformed Investors Related Post navigation Inside OpenAI’s Stargate Megafactory with Sam Altman | The Circuit ASX:WMG – Strategic Capital Raise Advances Mulga Tank Exploration Program
Every contribution fuels new features and improvements
Thank you for being part of our journey! 🚀
